logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

Swire Pacific B (00087) spent 1.86 million Hong Kong dollars on repurchasing 187,500 shares on September 20th.

date
18:05 20/09/2024
avatar
GMT Eight
The announcement was made by TAIGU Holdings Company B (00087) on September 20, 2024, stating that the company had invested 186.08...
SWIRE PACIFIC B (00087) announced that the company has repurchased 187,500 shares at a total cost of HK$1.8608 million on September 20, 2024, with a repurchase price ranging from HK$9.76 to HK$9.97 per share.
Related Articles
New Stock News | Wuhe and Boao submit applications to Hong Kong Stock Exchange
HK Stock
CONTEL (01912) and its related subsidiaries strongly deny the allegations made in the summons.
HK Stock
RIBOLIFE-B (06938): RBD7022 injection will soon start Phase III clinical trials in China for the treatment of hyperlipidemia indications.
New Stock News | Wuhe and Boao submit applications to Hong Kong Stock Exchange
CONTEL (01912) and its related subsidiaries strongly deny the allegations made in the summons.
HK Stock
RIBOLIFE-B (06938): RBD7022 injection will soon start Phase III clinical trials in China for the treatment of hyperlipidemia indications.
HK Stock
RECOMMEND
Hong Kong IPOs Start Year With Rapid Pace As Fundraising Jumps Tenfold And No First‑Day Declines
Hong Kong IPOs Start Year With Rapid Pace As Fundraising Jumps Tenfold And No First‑Day Declines
icon
02/03/2026
Hong Kong IPO Cornerstone Investors Have Subscribed HKD 40 Billion This Year
Hong Kong IPO Cornerstone Investors Have Subscribed HKD 40 Billion This Year
icon
02/03/2026
Over One Trillion Market Value Evaporates As Nvidia Reports Strong Results But Shares Plunge
Over One Trillion Market Value Evaporates As Nvidia Reports Strong Results But Shares Plunge
icon
02/03/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.